Ash Alizadeh, MD, PhD, Stanford Comprehensive Cancer Center, Stanford, CA, describes genetic testing in lymphoma and the identification of biomarkers that influence ongoing therapy. Whilst testing for genetic aberrations in genes such as MEK, BCL2, and BCL6 are routinely carried out in diagnosing large cell lymphomas, treatment regimens based on genetic information are seldom seen. Intense treatments in double-hit lymphoma (DHL) and other existing treatment strategies based on genetic information are controversial. However liquid biopsies can lead to more successful biomarker-driven therapies such as the use of tazemetostat in lymphomas with ECH2 mutations. This interview took place during the 2021 International Conference on Malignant Lymphoma (16-ICML).